Opus Genetics, Inc. (IRD) stock
IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30483% above fair value
$4.06−0.25 (-5.80%)
Close on Nov 12, 2026Market cap $337.78MP/E –Yield –
Opus Genetics cash
Cash and short-term investments held at the end of each period.
Opus Genetics's cash was $88.97M at Sep 30, 2026. For fiscal 2025 it was $45.09M, up 48.7% from the year before. Over ten years it grew 16.0% a year on average. The highest annual figure on record is $50.52M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.09M | +48.7% |
| FY2024 | Dec 31, 2024 | $30.32M | -40.0% |
| FY2023 | Dec 31, 2023 | $50.52M | +18.4% |
| FY2022 | Dec 31, 2022 | $42.68M | +72.4% |
| FY2021 | Dec 31, 2021 | $24.75M | +50.9% |
| FY2020 | Dec 31, 2020 | $16.40M | +34.4% |
| FY2019 | Dec 31, 2019 | $12.20M | +2605.1% |
| FY2018 | Dec 31, 2018 | $451.00K | -94.9% |
| FY2017 | Dec 31, 2017 | $8.90M | -23.1% |
| FY2016 | Dec 31, 2016 | $11.58M | +13.5% |
| FY2015 | Dec 31, 2015 | $10.20M | +3.8% |
| FY2014 | Dec 31, 2014 | $9.83M | -47.4% |
| FY2013 | Dec 31, 2013 | $18.69M | +38.6% |
| FY2012 | Dec 31, 2012 | $13.49M | +36.8% |
| FY2011 | Dec 31, 2011 | $9.86M | -20.1% |
| FY2010 | Dec 31, 2010 | $12.34M | +69.1% |
| FY2009 | Dec 31, 2009 | $7.30M | +1877.1% |
| FY2008 | Dec 31, 2008 | $369.13K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $88.97M | +188.7% |
| Q2 FY2026 | Jun 30, 2026 | $88.81M | +173.9% |
| Q1 FY2026 | Mar 31, 2026 | $59.96M | +43.5% |
| Q4 FY2025 | Dec 31, 2025 | $45.09M | +48.7% |
| Q3 FY2025 | Sep 30, 2025 | $30.82M | -15.9% |
| Q2 FY2025 | Jun 30, 2025 | $32.43M | -21.7% |
| Q1 FY2025 | Mar 31, 2025 | $41.79M | -11.4% |
| Q4 FY2024 | Dec 31, 2024 | $30.32M | -40.0% |
| Q3 FY2024 | Sep 30, 2024 | $36.64M | -13.5% |
| Q2 FY2024 | Jun 30, 2024 | $41.41M | +3.5% |
| Q1 FY2024 | Mar 31, 2024 | $47.17M | +20.9% |
| Q4 FY2023 | Dec 31, 2023 | $50.52M | +18.4% |
| Q3 FY2023 | Sep 30, 2023 | $42.36M | +203.5% |
| Q2 FY2023 | Jun 30, 2023 | $40.00M | +133.2% |
| Q1 FY2023 | Mar 31, 2023 | $39.01M | +101.3% |
| Q4 FY2022 | Dec 31, 2022 | $42.68M | +72.4% |
| Q3 FY2022 | Sep 30, 2022 | $13.96M | -38.3% |
| Q2 FY2022 | Jun 30, 2022 | $17.15M | -29.2% |
| Q1 FY2022 | Mar 31, 2022 | $19.38M | +82.9% |
| Q4 FY2021 | Dec 31, 2021 | $24.75M | +50.9% |
| Q3 FY2021 | Sep 30, 2021 | $22.63M | +179.4% |
| Q2 FY2021 | Jun 30, 2021 | $24.23M | +163.4% |
| Q1 FY2021 | Mar 31, 2021 | $10.60M | -3.7% |
| Q4 FY2020 | Dec 31, 2020 | $16.40M | +34.4% |
| Q3 FY2020 | Sep 30, 2020 | $8.10M | -41.7% |
| Q2 FY2020 | Jun 30, 2020 | $9.20M | +25.9% |
| Q1 FY2020 | Mar 31, 2020 | $11.00M | +79.7% |
| Q4 FY2019 | Dec 31, 2019 | $12.20M | +2605.1% |
| Q3 FY2019 | Sep 30, 2019 | $13.90M | +10.3% |
| Q2 FY2019 | Jun 30, 2019 | $7.31M | +43.5% |
| Q1 FY2019 | Mar 31, 2019 | $6.12M | -2.8% |
| Q4 FY2018 | Dec 31, 2018 | $451.00K | -94.9% |
| Q3 FY2018 | Sep 30, 2018 | $12.60M | +53.2% |
| Q2 FY2018 | Jun 30, 2018 | $5.09M | -42.0% |
| Q1 FY2018 | Mar 31, 2018 | $6.30M | -39.9% |
| Q4 FY2017 | Dec 31, 2017 | $8.90M | -23.1% |
| Q3 FY2017 | Sep 30, 2017 | $8.23M | – |
| Q2 FY2017 | Jun 30, 2017 | $8.79M | – |
| Q1 FY2017 | Mar 31, 2017 | $10.49M | – |
| Q4 FY2016 | Dec 31, 2016 | $11.58M | – |
See a number that looks wrong?